CSBio CSBio

X
[{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Extends Clinical Development Program for Finerenone With Phase II Study Investigating the Initial Combination Therapy with Empagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","amount":"$1,015.0 million","upfrontCash":"$15.0 million","newsHeadline":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MorphoSys"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreements, HIBio will obtain exclusive rights to develop and commercialize MOR202 (felzartamab) and MOR210 across autoimmune and inflammatory disease, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210.

            Lead Product(s): Felzartamab

            Therapeutic Area: Nephrology Product Name: MOR202

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: HIBio

            Deal Size: $1,015.0 million Upfront Cash: $15.0 million

            Deal Type: Licensing Agreement June 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The primary objective of the study is to demonstrate that the simultaneous initiation and combined use of finerenone and empagliflozin is superior to either empagliflozin alone, or finerenone alone, in reducing urine albumin-to-creatinine ratio (UACR).

            Lead Product(s): Finerenone,Empagliflozin

            Therapeutic Area: Nephrology Product Name: Kerendia

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY